BBO-11818 in Adult Subjects With KRAS Mutant Cancer

This study is testing a new experimental drug called BBO-11818 in adults with advanced cancers that carry a specific KRAS mutation — a genetic change found in several common cancers including lung, pancreatic, and colorectal cancer. The study aims to determine the right dose and early signs of effectiveness. **You may be eligible if...** - You are an adult with confirmed advanced or metastatic lung cancer (NSCLC), pancreatic cancer, colorectal cancer, or another solid tumor - Your tumor has a KRAS G12A, G12C, G12D, G12S, or G12V mutation - You have measurable disease on imaging - Your performance status is good (ECOG 0-1) **You may NOT be eligible if...** - You have had another malignancy within the last 2 years (certain exceptions may apply) - You have untreated brain metastases - You have a known allergy to BBO-11818 Talk to your doctor to see if this trial is right for you.